Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its upcoming participation in the Needham 24th Annual Virtual Healthcare Conference. The company's management will deliver a corporate overview presentation on Tuesday, April 8, 2025, at 11:45 am ET.
Interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available on the company's website within 48 hours following the event.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un leader nelle terapie RNAi, ha annunciato la sua prossima partecipazione alla 24ª Conferenza Virtuale Annuale sulla Salute di Needham. La direzione dell'azienda presenterà una panoramica aziendale martedì 8 aprile 2025, alle 11:45 ET.
Le parti interessate possono accedere a un webcast audio in diretta della presentazione attraverso la sezione Investitori del sito web di Alnylam all'indirizzo www.alnylam.com/events. Una registrazione della presentazione sarà disponibile sul sito dell'azienda entro 48 ore dopo l'evento.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un líder en terapias de RNAi, ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La dirección de la empresa presentará una visión general corporativa el martes 8 de abril de 2025, a las 11:45 am ET.
Las partes interesadas pueden acceder a un webcast de audio en vivo de la presentación a través de la sección de Inversores del sitio web de Alnylam en www.alnylam.com/events. Una repetición de la presentación estará disponible en el sitio web de la empresa dentro de las 48 horas posteriores al evento.
Alnylam Pharmaceuticals (Nasdaq: ALNY), RNAi 치료의 선두주자인, Needham 제24회 연례 가상 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. 회사 경영진은 2025년 4월 8일 화요일, 오전 11:45 ET에 기업 개요 발표를 진행할 예정입니다.
관심 있는 분들은 Alnylam 웹사이트의 투자자 섹션을 통해 발표의 실시간 오디오 웹캐스트에 접속할 수 있습니다. 발표의 재생은 이벤트 후 48시간 이내에 회사 웹사이트에서 제공될 것입니다.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un leader dans les thérapies par RNAi, a annoncé sa prochaine participation à la 24ème Conférence Virtuelle Annuelle sur la Santé de Needham. La direction de l'entreprise présentera un aperçu de l'entreprise le mardi 8 avril 2025, à 11h45 ET.
Les parties intéressées peuvent accéder à un webcast audio en direct de la présentation via la section Investisseurs du site web d'Alnylam à l'adresse www.alnylam.com/events. Un enregistrement de la présentation sera disponible sur le site de l'entreprise dans les 48 heures suivant l'événement.
Alnylam Pharmaceuticals (Nasdaq: ALNY), ein führendes Unternehmen im Bereich RNAi-Therapeutika, hat seine bevorstehende Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 8. April 2025, um 11:45 Uhr ET eine Unternehmensübersicht präsentieren.
Interessierte können über den Investorenbereich der Alnylam-Website unter www.alnylam.com/events auf ein Live-Audio-Webcast der Präsentation zugreifen. Eine Wiederholung der Präsentation wird innerhalb von 48 Stunden nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio® (inclisiran) and Qfitlia™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401950208/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When is Alnylam (ALNY) presenting at the Needham Healthcare Conference 2025?
How can investors watch Alnylam's (ALNY) Needham Conference presentation?
What type of presentation will Alnylam (ALNY) give at the Needham Conference?
How long will Alnylam's (ALNY) Needham Conference presentation be available for replay?
